Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

Colorectal cancer is the third most common cancer worldwide, and incidence is rising in
younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have …

Importance The available evidence regarding anti–epidermal growth factor receptor (EGFR)
inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) …

Importance Current third-line therapies for patients with metastatic colorectal cancer (MCRC)
have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors …

Esophageal cancer is a prevalent tumor of the digestive tract worldwide. The detection rate
of early-stage esophageal cancer is very low, and most patients are diagnosed with …

Simple Summary Rechallenge with epidermal growth factor (EGFR) inhibitors represents a
promising therapeutic strategy in patients with refractory RAS/BRAF wild-type metastatic …

Niclosamide is a drug used to treat parasitic infections. Recent studies have shown that
niclosamide may have a wide range of clinical applications and can be used to treat cancer …

The randomized phase II VELO trial showed that the addition of panitumumab to
trifluridine/tipiracil significantly improves progression‐free survival (PFS) as compared to …

Background High neutrophil-to-lymphocyte ratio (NLR) is a poor prognostic factor in
metastatic colorectal cancer (mCRC). Here we provide final results of CAVE mCRC trial, of …

Despite recent molecular and immunological advancements, prognosis of metastatic
colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and …